Sign inJoin waitlistJoin the waitlist

Caspian Oliai

Medical Director, UCLA Bone Marrow Stem Cell Laboratory · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · · · · ·

History

UCLA Bone Marrow Stem Cell Laboratory · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA David Geffen School of Medicine/UCLA Medical Center
Present

Hematology and Medical Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
2016–2019
Internal Medicine
UCLA David Geffen School of Medicine/UCLA Medical Center
2014–2016
California Pacific Medical Center
2012–2014
Drexel University College of Medicine/Hahnemann University
2011–2012
University of Pennsylvania
Drexel University College of Medicine
2007–2011
University of Miami
2003–2007

Research

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Cancer Discovery · 2023 · 95 citations
Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo
The Journal of Immunology · 2011 · 59 citations
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
Journal of Radiation Oncology · 2013 · First of 10 authors · 58 citations

Aaron Logan
10 papers
Lori Muffly
9 papers
DG
Daria Gaut
8 papers · 7 as a fellow
Gary Schiller
8 papers
Rasmus Hoeg
8 papers
RF
Rawan Faramand
7 papers
Bhagirathbhai Dholaria
6 papers
BS
Bijal Shah
6 papers
Gregory Roloff
6 papers · 3 as a fellow
Ibrahim Aldoss
6 papers
JL
Jessica Leonard
6 papers
Joshua Sasine
6 papers

Clinical trials

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Principal investigator · Withdrawn · Phase 1
Jonsson Comprehensive Cancer Center
2024–2026
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Principal investigator · Recruiting · Phase 1, Phase 2
Jonsson Comprehensive Cancer Center
2023–2028
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 1
Jonsson Comprehensive Cancer Center
2019–2023
CPX-351 Plus Enasidenib for Relapsed AML
Principal investigator · Active not recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2019–2024